Michael Jung, distinguished professor of chemistry, and Daniel Geschwind, distinguished professor of neurology and psychiatry at the David Geffen School of Medicine at UCLA, were awarded the Amgen Early Innovator Award at the UCLA Biomedical and Life Science Innovation Day 2018 for their research into Alzheimer’s disease.

The award supports the translation of promising academic research into technologies that benefit patients. Jung and Geschwind were awarded $75,000 to further the research conducted in Geschwind’s laboratory.

Jung and Geschwind are partners on a joint collaborative project seeking to develop an effective drug to treat Alzheimer’s patients. Gershwind’s group is carrying out the biological testing portion of the research and Jung’s group is determining the structure–activity relationship for Geschwind’s lead molecules using organic chemistry methods.